Addressing the nation’s opioid epidemic, improving health care access, and strengthening the Food and Drug Administration (FDA)’s workforce and risk management framework are some of the goals put forward by FDA Commissioner Scott Gottlieb, M.D., in the agency’s 2018 Strategic Policy Roadmap.
To help tackle opioid addiction – which kills 91 Americans every day – FDA vows to ensure better prescription practices, support medication-assisted treatment for those addicted (in addition to counseling), and increase efforts to curb the illegal shipment of opioids into the U.S.
The agency also plans to streamline the process through which generic drugs enter the market, fueling competition, in an effort to lower drug prices.
To better keep pace with new research in gene- and cell-based technologies, targeted medicines and medical devices, FDA will evaluate its current hiring and pay practices to make sure it attracts and maintains a workforce robust enough to ensure the safety of new therapies while getting them to Americans as quickly as possible.
“These goals – and the work we do together in achieving them – go to the heart of our mission of advancing and protecting public health, while maintaining our commitment to the scientific standards that make FDA a recognized global leader, and a gold standard for product review,” Gottlieb said.
Click here to learn more.